You just read:

Denovo Biopharma Receives FDA's Permission to Proceed a Phase 3 Clinical Trial with DB102 (Enzastaurin) In the First Line Treatment of High Risk DLBCL

News provided by

Denovo Biopharma

Oct 24, 2017, 06:00 ET